"Pill-in-Pocket" anticoagulation for stroke prevention in atrial fibrillation.
Level 5 - mechanism / opinion, no new human data
Narrative review with no original human data or systematic synthesis
PubMed 36806796 · doi:10.1111/jce.15866
What was done
This narrative review synthesizes literature on the temporal relationship between multihour atrial fibrillation episodes and stroke risk, explores the rationale for targeted pill-in-the-pocket anticoagulation versus continuous therapy, and introduces the design context of the REACT-AF clinical trial.
What was found
The abstract reports no numerical findings or comparative statistics. It summarizes the theoretical and observational basis for a critical duration threshold of atrial fibrillation that may benefit from anticoagulation.
Why it matters
A targeted anticoagulation strategy guided by arrhythmia episodes could potentially decrease bleeding risks in select patients with low atrial fibrillation burden compared to lifelong continuous therapy.
Limits
The paper is a narrative review providing no primary clinical data, quantitative meta-analysis, or systematic search methodology. The clinical safety and efficacy of episodic anticoagulation remain unproven pending prospective randomized trial results.
Cited by
- supports The REACT clinical trial is investigating whether patients with intermittent atrial fibrillation can take anticoagulation temporarily only when episodes occur rather than on a continuous, permanent basis.